Developer docs
API playgroundTry for free, no card

Search company profiles

amgen uk & ie

Full company profile

uuid02m5em5

Namestring
amgen uk & ie
Legal namestring
Amgen Limited (UK entity); Amgen Ireland Limited (Ireland entity)
Websiteurl
amgen.co.uk
Company typeenum
Private
Founded yearint
1980
Descriptiontext

Amgen UK & Ireland is the UK and Republic of Ireland operating subsidiary of Amgen Inc. (NASDAQ: AMGN), one of the world's largest independent biotechnology companies founded in 1980 as Applied Molecular Genetics. Headquartered at Cambridge Science Park (over 25 years of presence) with a Development Centre in Uxbridge opened in 2007, the subsidiary employs approximately 650 staff in the UK and is described by the parent as one of its largest sites outside California, serving as the European hub for research and development. The legal entities are Amgen Limited (England and Wales) and Amgen Ireland Limited (Republic of Ireland).

Amgen UK develops, supplies, and supports a portfolio of 19 branded biologic prescription medicines spanning four therapeutic areas: oncology and haematology (BLINCYTO, Kyprolis, Vectibix, LUMYKRAS, IMDYLLTRA, IMLYGIC, Nplate), inflammation (AMGEVITA, OTEZLA, WEZENLA), bone health (Prolia, XGEVA), and cardiovascular and rare disease (Repatha, BEKEMV, Mimpara, Parsabiv, Aranesp, Neulasta, NEUPOGEN). The portfolio also includes one of the world's largest biosimilars franchises. Manufacturing relies on biologic production using living cells in bioreactors up to 20,000 litres, with over 250 quality checks per product, supported by R&D capabilities including Generative Biology (AI/ML plus biology for protein drug discovery) and the deCODE genetics population genomics platform.

Revenue is generated through direct prescription-medicine sales to the NHS and hospital systems via an enterprise field-sales motion, with orders managed through the Amgen Direct online portal. The company engages in collaborative working agreements and joint working projects with named NHS partners (Belfast HSCT, University Hospitals Birmingham, Guy's & St Thomas', Manchester University NHSFT, Sheffield Teaching Hospitals, Hywel Dda UHB) covering medicines optimisation, service redesign, and population health initiatives such as the QuicDNA liquid biopsy lung cancer programme and Next Generation Population Health cardiovascular risk modelling. The UK entity is fully ABPI Code-compliant, holds UK Binding Corporate Rules for cross-border data transfers, and operates the Amgen Foundation's science-education programmes in the UK.

Short descriptiontext

Amgen UK & Ireland is the UK and Ireland subsidiary of Amgen Inc., developing and supplying biologic medicines in oncology, inflammation, bone health, and cardiovascular disease to NHS Trusts, hospitals, and specialists through direct enterprise sales.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersUxbridge, United Kingdom
HQ citystring
Uxbridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologic medicines, oncology therapeutics, biosimilars portfolio, bone health treatments, cardiovascular biologics
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Prescription Biologic Medicines
TypeOne Time License
Description

Amgen discovers, develops, manufactures and delivers innovative biologic medicines to patients with serious illnesses. Revenue is generated through product sales of prescription medicines to healthcare systems and patients.

amgen.co.uk
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Amgen UK & IE discovers (via the global Amgen pipeline), supplies, and supports the use of biologic prescription medicines to UK and Irish healthcare providers. Its portfolio includes 19 branded biologics and biosimilars covering oncology, haematology, inflammation, bone health, cardiovascular disease, and rare diseases, delivered through direct supply to NHS Trusts and hospitals and supported by field medical teams. The Cambridge headquarters and Uxbridge Development Centre also host European R&D activities for the parent group.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • More than 750,000 people in 65+ countries prescribed Amgen biosimilars
+3 more records
Product overview1 text field

Amgen UK is a biotechnology company offering a diversified portfolio of innovative biologic medicines and biosimilars. The company operates across four main therapeutic areas: oncology and hematology, inflammation, bone health, and cardiovascular disease. Its portfolio includes 19 branded prescription medicines including targeted cancer therapies (BLINCYTO, Kyprolis, Vectibix, LUMYKRAS), supportive care products (NEUPOGEN, Neulasta, Nplate), inflammation treatments (AMGEVITA, OTEZLA, WEZENLA), bone health therapies (Prolia, XGEVA), cardiovascular medicines (Repatha), and rare disease treatments (BEKEMV, Mimpara, Parsabiv). The portfolio also includes breakthrough therapies (IMDYLLTRA for small cell lung cancer, IMLYGIC for melanoma). Amgen manufactures biologic medicines using living cells through complex biomanufacturing processes and offers both innovator biologics and biosimilars backed by over 40 years of biotechnology experience.

Product and service19 records
1AMGEVITA (adalimumab)
CategoryInflammation biosimilars
Description

A biosimilar of adalimumab used for treating inflammatory conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease; supplied to NHS hospitals for specialist prescribing.

2Aranesp (darbepoetin alfa)
CategoryHaematology / supportive care
Description

An erythropoiesis-stimulating agent used to treat anaemia, particularly in patients with chronic kidney disease or cancer; supplied to NHS hospitals and specialist centres.

3BEKEMV (eculizumab)
CategoryRare disease biologics
Description

A monoclonal antibody used for treating paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS); supplied to NHS specialist centres.

4BLINCYTO (blinatumomab)
CategoryOncology biologics
Description

A bispecific T-cell engager (BiTE) antibody used for treating acute lymphoblastic leukaemia (ALL); supplied to NHS specialist oncology centres.

5IMDYLLTRA (tarlatamab)
CategoryOncology biologics
Description

A bispecific antibody targeting DLL3 for treating small cell lung cancer; supplied to specialist oncology centres.

6IMLYGIC (talimogene laherparepvec)
CategoryOncology biologics
Description

An oncolytic viral therapy used for treating melanoma lesions in the skin and lymph nodes; supplied to specialist oncology centres.

7Kyprolis (carfilzomib)
CategoryOncology biologics
Description

A proteasome inhibitor used for treating multiple myeloma in patients who have received at least one prior therapy; supplied to NHS specialist haematology centres.

8LUMYKRAS (sotorasib)
CategoryOncology biologics
Description

A KRAS G12C inhibitor used for treating non-small cell lung cancer with KRAS G12C mutations; supplied to specialist oncology centres.

9Mimpara (cinacalcet HCl)
CategoryRare disease / nephrology
Description

A calcimimetic agent used for treating secondary hyperparathyroidism in patients with chronic kidney disease; supplied to NHS renal units.

10NEUPOGEN (filgrastim)
CategoryHaematology / supportive care
Description

A filgrastim formulation used to reduce the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy; supplied to NHS oncology centres.

11Neulasta (pegfilgrastim)
CategoryHaematology / supportive care
Description

A pegylated filgrastim formulation used to reduce the duration of neutropenia and febrile neutropenia in patients receiving chemotherapy; supplied to NHS oncology centres.

12Nplate (romiplostim)
CategoryHaematology / supportive care
Description

A thrombopoietin receptor agonist used for treating immune thrombocytopenia (ITP) in adult patients; supplied to NHS specialist haematology centres.

13OTEZLA (apremilast)
CategoryInflammation therapeutics
Description

A PDE4 inhibitor used for treating psoriatic arthritis and moderate to severe plaque psoriasis; supplied to NHS specialist dermatology and rheumatology centres.

14Parsabiv (etelcalcetide)
CategoryRare disease / nephrology
Description

A calcimimetic agent used for treating secondary hyperparathyroidism in adult patients with chronic kidney disease on haemodialysis; supplied to NHS renal units.

15Prolia (denosumab)
CategoryBone health biologics
Description

A RANKL inhibitor used for treating osteoporosis in postmenopausal women and men at increased risk of fracture; supplied to NHS bone health services.

16Repatha (evolocumab)
CategoryCardiovascular biologics
Description

A PCSK9 inhibitor used for treating hypercholesterolaemia and reducing cardiovascular events; supplied to NHS lipid clinics and cardiology services.

17Vectibix (panitumumab)
CategoryOncology biologics
Description

An EGFR inhibitor used for treating metastatic colorectal cancer with wild-type RAS tumours; supplied to NHS specialist oncology centres.

18WEZENLA (ustekinumab)
CategoryInflammation biosimilars
Description

A biosimilar of ustekinumab used for treating plaque psoriasis, psoriatic arthritis, and Crohn's disease; supplied to NHS specialist centres.

19XGEVA (denosumab)
CategoryBone health biologics
Description

A RANKL inhibitor used for preventing skeletal-related events in patients with bone metastases from solid tumours and for treating giant cell tumour of bone; supplied to NHS oncology centres.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1All-Wales Medical Genomic Services (AWMGS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-01
Description

QuicDNA project partnership for accelerating lung cancer diagnosis through innovative liquid biopsy (ctDNA) testing. Multiple Welsh Health Boards involved.

amgen.co.uk
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Amgen Foundation is exclusive sponsor of Khan Academy's online biology resources since 2015, covering high school and college-level biology content.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2006-01-01
Description

Undergraduate summer research experience programme hosted at 24 premier institutions worldwide. European programme symposium held at University of Cambridge annually.

4Belfast Health & Social Care Trust
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative working agreement focused on patient care improvement initiatives and medicines optimisation.

amgen.co.uk
5University Hospitals Birmingham NHS Foundation Trust
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative working project for improving patient outcomes and healthcare service delivery.

amgen.co.uk
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative working partnership for patient care initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative working agreement for healthcare improvement projects.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Completed collaborative working outcomes project for patient care improvement.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Next Generation Population Health project - cardiovascular disease risk prediction and prevention initiative in partnership with Swansea Bay University Health Board and Swansea University.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership in Next Generation Population Health project for cardiovascular disease research.

11Patient Advocacy Groups (UK)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnerships with patient advocacy groups to support programmes that benefit patients. Annual funding disclosures made publicly available. Includes various UK patient organisations.

amgen.co.uk
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Science education programme providing teachers with professional development and education materials, loaning research-grade equipment to high schools free of charge. Over one million students reached worldwide.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Free online science learning platform developed at Harvard University, funded by Amgen Foundation. Provides personalised instruction and virtual lab experiences.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Sanofi UK
TypeBroad incumbent
Description

UK subsidiary of French pharmaceutical major Sanofi with biologic medicines in immunology, rare diseases, and oncology. Competes with Amgen UK in inflammatory disease biologics and similar NHS hospital supply arrangements.

2Bristol-Myers Squibb UK
TypeBroad incumbent
Description

UK subsidiary of Bristol-Myers Squibb, a major biologic medicines company in oncology, immunology, and cardiovascular disease. Direct competitor in NHS hospital specialty markets for cancer biologics and similar BiTE technology (BLINCYTO competitive set).

TypeBroad incumbent
Description

UK subsidiary of Swiss pharmaceutical giant Roche, a global leader in biologic medicines for oncology and immunology. Direct competitor in NHS hospital channels for cancer biologics and similar biosimilars portfolio.

4Johnson & Johnson Innovative Medicine UK
TypeBroad incumbent
Description

UK subsidiary of Johnson & Johnson's pharmaceutical segment with biologic medicines in oncology, immunology, and pulmonary hypertension. Competes with Amgen UK in similar specialty hospital markets through NHS supply channels.

TypeBroad incumbent
Description

UK subsidiary of Swiss pharmaceutical major Novartis with strong biologic medicines presence in oncology and immunology. Competes with Amgen UK in similar therapeutic areas through NHS hospital supply arrangements.

TypeBroad incumbent
Description

UK subsidiary of AbbVie, a global leader in biologic medicines particularly in immunology (Humira franchise) and oncology. Direct competitor in inflammatory disease biologic market and emerging biosimilar competitor in UK.

TypeBroad incumbent
Description

UK subsidiary of global pharmaceutical leader Pfizer with significant biologic medicines portfolio and growing biosimilars business. Competes with Amgen UK in oncology, inflammation, and rare disease biologic markets via NHS channels.

TypeBroad incumbent
Description

UK-headquartered global pharmaceutical company with a major biologic medicines franchise in oncology, cardiovascular, and respiratory disease. Direct overlap with Amgen UK in supplying biologic medicines to NHS hospitals across multiple therapeutic areas.

TypeBroad incumbent
Description

UK subsidiary of Eli Lilly with growing biologic medicines portfolio in oncology, immunology, and diabetes/obesity. Increasingly competes with Amgen UK in NHS specialty channels, particularly in cardiometabolic and inflammation areas.

TypeBroad incumbent
Description

UK-headquartered global pharmaceutical company with biologic medicines in oncology, immunology, and rare diseases. Competes with Amgen UK in NHS hospital specialty channels and has overlapping R&D infrastructure in UK life sciences clusters.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

amgen uk & ie

Biopharmaceuticalsamgen.co.uk

Amgen UK & Ireland is the UK and Ireland subsidiary of Amgen Inc., developing and supplying biologic medicines in oncology, inflammation, bone health, and cardiovascular disease to NHS Trusts, hospitals, and specialists through direct enterprise sales.

What amgen uk & ie does

Amgen UK & Ireland is the UK and Republic of Ireland operating subsidiary of Amgen Inc. (NASDAQ: AMGN), one of the world's largest independent biotechnology companies founded in 1980 as Applied Molecular Genetics. Headquartered at Cambridge Science Park (over 25 years of presence) with a Development Centre in Uxbridge opened in 2007, the subsidiary employs approximately 650 staff in the UK and is described by the parent as one of its largest sites outside California, serving as the European hub for research and development. The legal entities are Amgen Limited (England and Wales) and Amgen Ireland Limited (Republic of Ireland).

Amgen UK develops, supplies, and supports a portfolio of 19 branded biologic prescription medicines spanning four therapeutic areas: oncology and haematology (BLINCYTO, Kyprolis, Vectibix, LUMYKRAS, IMDYLLTRA, IMLYGIC, Nplate), inflammation (AMGEVITA, OTEZLA, WEZENLA), bone health (Prolia, XGEVA), and cardiovascular and rare disease (Repatha, BEKEMV, Mimpara, Parsabiv, Aranesp, Neulasta, NEUPOGEN). The portfolio also includes one of the world's largest biosimilars franchises. Manufacturing relies on biologic production using living cells in bioreactors up to 20,000 litres, with over 250 quality checks per product, supported by R&D capabilities including Generative Biology (AI/ML plus biology for protein drug discovery) and the deCODE genetics population genomics platform.

Revenue is generated through direct prescription-medicine sales to the NHS and hospital systems via an enterprise field-sales motion, with orders managed through the Amgen Direct online portal. The company engages in collaborative working agreements and joint working projects with named NHS partners (Belfast HSCT, University Hospitals Birmingham, Guy's & St Thomas', Manchester University NHSFT, Sheffield Teaching Hospitals, Hywel Dda UHB) covering medicines optimisation, service redesign, and population health initiatives such as the QuicDNA liquid biopsy lung cancer programme and Next Generation Population Health cardiovascular risk modelling. The UK entity is fully ABPI Code-compliant, holds UK Binding Corporate Rules for cross-border data transfers, and operates the Amgen Foundation's science-education programmes in the UK.

amgen uk & ie firmographics

Firmographics
Name
amgen uk & ie
Legal name
Amgen Limited (UK entity); Amgen Ireland Limited (Ireland entity)
Website
https://amgen.co.uk
Company type
Private
Founded year
1980
Operating status
Operating
Short description
Amgen UK & Ireland is the UK and Ireland subsidiary of Amgen Inc., developing and supplying biologic medicines in oncology, inflammation, bone health, and cardiovascular disease to NHS Trusts, hospitals, and specialists through direct enterprise sales.
Ownership category
akta.pro rank

amgen uk & ie industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Biologic medicines
  • Oncology therapeutics
  • Biosimilars portfolio
  • Bone health treatments
  • Cardiovascular biologics

Where amgen uk & ie is headquartered

Location

Headquarters

HQ city
Uxbridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

amgen uk & ie business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Prescription Biologic Medicines: Amgen discovers, develops, manufactures and delivers innovative biologic medicines to patients with serious illnesses. Revenue is generated through product sales of prescription medicines to healthcare systems and patients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

amgen uk & ie product offering

Product offering

Core offering

Amgen UK & IE discovers (via the global Amgen pipeline), supplies, and supports the use of biologic prescription medicines to UK and Irish healthcare providers. Its portfolio includes 19 branded biologics and biosimilars covering oncology, haematology, inflammation, bone health, cardiovascular disease, and rare diseases, delivered through direct supply to NHS Trusts and hospitals and supported by field medical teams. The Cambridge headquarters and Uxbridge Development Centre also host European R&D activities for the parent group.

Product overview

Amgen UK is a biotechnology company offering a diversified portfolio of innovative biologic medicines and biosimilars. The company operates across four main therapeutic areas: oncology and hematology, inflammation, bone health, and cardiovascular disease. Its portfolio includes 19 branded prescription medicines including targeted cancer therapies (BLINCYTO, Kyprolis, Vectibix, LUMYKRAS), supportive care products (NEUPOGEN, Neulasta, Nplate), inflammation treatments (AMGEVITA, OTEZLA, WEZENLA), bone health therapies (Prolia, XGEVA), cardiovascular medicines (Repatha), and rare disease treatments (BEKEMV, Mimpara, Parsabiv). The portfolio also includes breakthrough therapies (IMDYLLTRA for small cell lung cancer, IMLYGIC for melanoma). Amgen manufactures biologic medicines using living cells through complex biomanufacturing processes and offers both innovator biologics and biosimilars backed by over 40 years of biotechnology experience.

Differentiator

Problem solved

Functional benefit

Products and services

  • AMGEVITA (adalimumab) A biosimilar of adalimumab used for treating inflammatory conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease; supplied to NHS hospitals for specialist prescribing.
  • Aranesp (darbepoetin alfa) An erythropoiesis-stimulating agent used to treat anaemia, particularly in patients with chronic kidney disease or cancer; supplied to NHS hospitals and specialist centres.
  • BEKEMV (eculizumab) A monoclonal antibody used for treating paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS); supplied to NHS specialist centres.
  • BLINCYTO (blinatumomab) A bispecific T-cell engager (BiTE) antibody used for treating acute lymphoblastic leukaemia (ALL); supplied to NHS specialist oncology centres.
  • IMDYLLTRA (tarlatamab) A bispecific antibody targeting DLL3 for treating small cell lung cancer; supplied to specialist oncology centres.
  • IMLYGIC (talimogene laherparepvec) An oncolytic viral therapy used for treating melanoma lesions in the skin and lymph nodes; supplied to specialist oncology centres.
  • Kyprolis (carfilzomib) A proteasome inhibitor used for treating multiple myeloma in patients who have received at least one prior therapy; supplied to NHS specialist haematology centres.
  • LUMYKRAS (sotorasib) A KRAS G12C inhibitor used for treating non-small cell lung cancer with KRAS G12C mutations; supplied to specialist oncology centres.
  • Mimpara (cinacalcet HCl) A calcimimetic agent used for treating secondary hyperparathyroidism in patients with chronic kidney disease; supplied to NHS renal units.
  • NEUPOGEN (filgrastim) A filgrastim formulation used to reduce the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy; supplied to NHS oncology centres.
  • Neulasta (pegfilgrastim) A pegylated filgrastim formulation used to reduce the duration of neutropenia and febrile neutropenia in patients receiving chemotherapy; supplied to NHS oncology centres.
  • Nplate (romiplostim) A thrombopoietin receptor agonist used for treating immune thrombocytopenia (ITP) in adult patients; supplied to NHS specialist haematology centres.
  • OTEZLA (apremilast) A PDE4 inhibitor used for treating psoriatic arthritis and moderate to severe plaque psoriasis; supplied to NHS specialist dermatology and rheumatology centres.
  • Parsabiv (etelcalcetide) A calcimimetic agent used for treating secondary hyperparathyroidism in adult patients with chronic kidney disease on haemodialysis; supplied to NHS renal units.
  • Prolia (denosumab) A RANKL inhibitor used for treating osteoporosis in postmenopausal women and men at increased risk of fracture; supplied to NHS bone health services.
  • Repatha (evolocumab) A PCSK9 inhibitor used for treating hypercholesterolaemia and reducing cardiovascular events; supplied to NHS lipid clinics and cardiology services.
  • Vectibix (panitumumab) An EGFR inhibitor used for treating metastatic colorectal cancer with wild-type RAS tumours; supplied to NHS specialist oncology centres.
  • WEZENLA (ustekinumab) A biosimilar of ustekinumab used for treating plaque psoriasis, psoriatic arthritis, and Crohn's disease; supplied to NHS specialist centres.
  • XGEVA (denosumab) A RANKL inhibitor used for preventing skeletal-related events in patients with bone metastases from solid tumours and for treating giant cell tumour of bone; supplied to NHS oncology centres.

Quantifiable outcome

  • More than 750,000 people in 65+ countries prescribed Amgen biosimilars
  • +3 more outcomes

Companies that use amgen uk & ie

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles1 record

amgen uk & ie technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

amgen uk & ie partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • All-Wales Medical Genomic Services (AWMGS)coreStrategic or Co-development Partner · 1 March 2023QuicDNA project partnership for accelerating lung cancer diagnosis through innovative liquid biopsy (ctDNA) testing. Multiple Welsh Health Boards involved.
  • Khan AcademyminorStrategic or Co-development Partner · 1 January 2015Amgen Foundation is exclusive sponsor of Khan Academy's online biology resources since 2015, covering high school and college-level biology content.
  • Amgen Scholars - European Programme (University of Cambridge)minorStrategic or Co-development Partner · 1 January 2006Undergraduate summer research experience programme hosted at 24 premier institutions worldwide. European programme symposium held at University of Cambridge annually.
  • Belfast Health & Social Care TrustcoreStrategic or Co-development PartnerCollaborative working agreement focused on patient care improvement initiatives and medicines optimisation.
  • University Hospitals Birmingham NHS Foundation TrustcoreStrategic or Co-development PartnerCollaborative working project for improving patient outcomes and healthcare service delivery.
  • Guy's & St Thomas' NHS Foundation TrustcoreStrategic or Co-development PartnerCollaborative working partnership for patient care initiatives.
  • Manchester University NHS Foundation TrustcoreStrategic or Co-development PartnerCollaborative working agreement for healthcare improvement projects.
  • Sheffield Teaching Hospitals NHS Foundation TrustcoreStrategic or Co-development PartnerCompleted collaborative working outcomes project for patient care improvement.
  • Hywel Dda University Health BoardcoreStrategic or Co-development PartnerNext Generation Population Health project - cardiovascular disease risk prediction and prevention initiative in partnership with Swansea Bay University Health Board and Swansea University.
  • Swansea UniversitycoreStrategic or Co-development PartnerAcademic partnership in Next Generation Population Health project for cardiovascular disease research.
  • Patient Advocacy Groups (UK)coreStrategic or Co-development PartnerPartnerships with patient advocacy groups to support programmes that benefit patients. Annual funding disclosures made publicly available. Includes various UK patient organisations.
  • Amgen Biotech Experience - UK Secondary SchoolsminorStrategic or Co-development PartnerScience education programme providing teachers with professional development and education materials, loaning research-grade equipment to high schools free of charge. Over one million students reached worldwide.
  • LabXchange (Harvard University)minorStrategic or Co-development PartnerFree online science learning platform developed at Harvard University, funded by Amgen Foundation. Provides personalised instruction and virtual lab experiences.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

amgen uk & ie competitors and assessment

Company assessment

Broad incumbents

  • Sanofi UK: UK subsidiary of French pharmaceutical major Sanofi with biologic medicines in immunology, rare diseases, and oncology. Competes with Amgen UK in inflammatory disease biologics and similar NHS hospital supply arrangements.
  • Bristol-Myers Squibb UK: UK subsidiary of Bristol-Myers Squibb, a major biologic medicines company in oncology, immunology, and cardiovascular disease. Direct competitor in NHS hospital specialty markets for cancer biologics and similar BiTE technology (BLINCYTO competitive set).
  • Roche UK: UK subsidiary of Swiss pharmaceutical giant Roche, a global leader in biologic medicines for oncology and immunology. Direct competitor in NHS hospital channels for cancer biologics and similar biosimilars portfolio.
  • Johnson & Johnson Innovative Medicine UK: UK subsidiary of Johnson & Johnson's pharmaceutical segment with biologic medicines in oncology, immunology, and pulmonary hypertension. Competes with Amgen UK in similar specialty hospital markets through NHS supply channels.
  • Novartis UK: UK subsidiary of Swiss pharmaceutical major Novartis with strong biologic medicines presence in oncology and immunology. Competes with Amgen UK in similar therapeutic areas through NHS hospital supply arrangements.
  • AbbVie UK: UK subsidiary of AbbVie, a global leader in biologic medicines particularly in immunology (Humira franchise) and oncology. Direct competitor in inflammatory disease biologic market and emerging biosimilar competitor in UK.
  • Pfizer UK: UK subsidiary of global pharmaceutical leader Pfizer with significant biologic medicines portfolio and growing biosimilars business. Competes with Amgen UK in oncology, inflammation, and rare disease biologic markets via NHS channels.
  • AstraZeneca UK: UK-headquartered global pharmaceutical company with a major biologic medicines franchise in oncology, cardiovascular, and respiratory disease. Direct overlap with Amgen UK in supplying biologic medicines to NHS hospitals across multiple therapeutic areas.
  • Eli Lilly UK: UK subsidiary of Eli Lilly with growing biologic medicines portfolio in oncology, immunology, and diabetes/obesity. Increasingly competes with Amgen UK in NHS specialty channels, particularly in cardiometabolic and inflammation areas.
  • GSK UK: UK-headquartered global pharmaceutical company with biologic medicines in oncology, immunology, and rare diseases. Competes with Amgen UK in NHS hospital specialty channels and has overlapping R&D infrastructure in UK life sciences clusters.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

amgen uk & ie compliance and trust

Trust signal

Compliance3 records

amgen uk & ie financial estimates

Financial estimate

Revenue estimate

Valuation estimate

amgen uk & ie leadership team

Management profile

Number of profiles

Profiles2 records

amgen uk & ie subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

amgen uk & ie funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

amgen uk & ie M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about amgen uk & ie

What does amgen uk & ie do?

Amgen UK & IE discovers (via the global Amgen pipeline), supplies, and supports the use of biologic prescription medicines to UK and Irish healthcare providers. Its portfolio includes 19 branded biologics and biosimilars covering oncology, haematology, inflammation, bone health, cardiovascular disease, and rare diseases, delivered through direct supply to NHS Trusts and hospitals and supported by field medical teams. The Cambridge headquarters and Uxbridge Development Centre also host European R&D activities for the parent group.

Is amgen uk & ie a public or private company?

amgen uk & ie is a private company. It is classified as corporate owned and is currently operating.

When was amgen uk & ie founded?

amgen uk & ie was founded in 1980.

Where is amgen uk & ie based?

amgen uk & ie is headquartered in Uxbridge, United Kingdom, in the Europe region.

How does amgen uk & ie make money?

One revenue line is on record: prescription Biologic Medicines.

Who are amgen uk & ie's main competitors?

Broad incumbents on record are Sanofi UK, Bristol-Myers Squibb UK, Roche UK, Johnson & Johnson Innovative Medicine UK, Novartis UK, AbbVie UK, Pfizer UK, AstraZeneca UK, Eli Lilly UK and GSK UK.

Does amgen uk & ie have an API?

No public API is recorded for amgen uk & ie.

What industry is amgen uk & ie in?

amgen uk & ie's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales